Introduction
============

Osteoporosis is a progressive systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.[@b1-dddt-10-509] Changes in bone turnover with aging are responsible for bone loss and play a major role in osteoporosis. An imbalance in bone turnover impacts on bone strength as a result of reductions in bone volume and mineralization, loss of trabeculae, deterioration of trabecular connectivity, and the formation of resorption cavities and trabecular perforations. Therefore, an increase in bone turnover where resorption exceeds formation is not only inversely correlated with bone mineral density (BMD), but may also alter bone architecture and porosity, increasing the risk of fracture beyond that due to reduced BMD, and can therefore be an independent predictor of fracture risk.[@b2-dddt-10-509]--[@b5-dddt-10-509]

Bone density scanning using dual-energy X-ray absorpiometry is currently the most commonly used means of measuring BMD. It is typically used to diagnose and follow osteoporosis. The World Health Organization (WHO) has established criteria for making the diagnosis of osteoporosis, as well as determining levels that predict higher chances of fractures. These criteria are based on comparison of the BMD of the patient to that of a typical healthy, young female. BMD values that fall 2.5 standard deviations below the average for the healthy, young female's BMD are diagnosed as osteoporotic. BMD values less than the healthy, young female, but not 2.5 standard deviations below the average are referred to as osteopenic. In addition to serial BMD measurements, biochemical markers of bone turnover are also widely used to monitor treatment response, since they are noninvasive and relatively cheap compared with dual-energy X-ray absorptiometry.

Formation markers are products from the action of osteoblasts. These include bone-specific alkaline phosphatase (BALP), procollagen type 1 amino-terminal propeptide (PINP), osteocalcin (or bone GLA-protein), and procollagen type 1 carboxy-terminal propeptide (P1CP). Resorption markers are products from the action of osteoclasts. These include carboxy-terminal telopeptide cross-linked type 1 collagen (CTX), type I collagen amino-terminal telopeptide (NTX), and urine deoxypyridinoline.

Vitamin D metabolism plays a critical role in the regulation of mineral and bone homeostasis.[@b6-dddt-10-509] The active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1α,25-(OH)2D3), acts through the vitamin D receptor (VDR) present on target cells such as osteoblasts and osteoclasts[@b7-dddt-10-509],[@b8-dddt-10-509] to stimulate calcium absorption and reabsorption while blocking both the synthesis and secretion of another essential regulator of mineral balance, the parathyroid hormone (PTH).[@b9-dddt-10-509] At least two mechanisms are involved in vitamin D-mediated regulation of mineral and bone homeostasis: first, it binds to the VDR on osteoblastic cells and regulates osteoclastic activity via the osteoprotegerin (OPG)/receptor activator nuclear factor kB (RANK) system;[@b10-dddt-10-509] second, it secures a supersaturated state of calcium--phosphorus products in the blood, enabling osteoid mineralization.[@b11-dddt-10-509] Due to its calcemic activity and its potential role in promoting osteoclastic bone resorption, the use of vitamin D in the treatment of osteoporosis has been hindered.[@b12-dddt-10-509]--[@b14-dddt-10-509] However, much effort has been made to synthesize compounds that would retain only the differentiation and antiproliferative effects of 1α,25-(OH)2D3 and allow for safer usage and less side effects.[@b15-dddt-10-509],[@b16-dddt-10-509] In fact, the active form of vitamin D (1α,25-dihydroxyvitamin D3, calcitriol) and its prodrug (1α-hydroxyvitamin D3, alfacalcidol) have been approved for the treatment of osteoporosis in Japan.[@b17-dddt-10-509] Both calcitriol and alfacalcidol have been shown to increase BMD[@b18-dddt-10-509],[@b19-dddt-10-509] and reduce the risk of vertebral and nonvertebral fractures.[@b20-dddt-10-509] --[@b22-dddt-10-509] Eldecalcitol (ELD), formerly known as ED-71 that was developed in the early 1980s, is an analog of 1α,25-(OH)2D3 bearing a hydroxypropyloxy residue at the 2β position. In a rat ovariectomized model of osteoporosis, ELD has been demonstrated to lower biochemical and histological parameters of bone resorption.[@b23-dddt-10-509] Further study showed that these effects on bone were observed without sustained hypercalcemia or hypercalciuria.[@b24-dddt-10-509] ELD has also been approved as a drug for treatment of osteoporosis in Japan. In the recent years, a few clinical trials have been conducted to examine the efficacy of ELD in treating osteoporosis. This study was aimed to summarize the results of these clinical trials and evaluating the clinical effects of ELD on lumbar and hip BMD, and bone turnover markers (BTMs) in patients with osteoporosis.

Methods
=======

Literature search and study selection
-------------------------------------

Databases MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched till February 18, 2015 to identify all potential clinical trials using ELD for the treatment of osteoporosis. We performed the literature search using the following search term: (eldecalcitol OR ED-71). After excluding review articles, basic studies, animal studies, pharmacokinetic studies, articles in languages other than English, and conference abstracts, we identified a total of eleven clinical studies investigating the efficacy of ELD in treatment of osteoporosis. If the same study had been published in different articles, we selected the most recent publication or the publication covering most detailed information. Literature search was repeated using the same databases and search terms during the revision of this article and no new study was found.

Data extraction and quality assessment
--------------------------------------

For the meta-analysis study, we chose lumber BMD, hip BMD, and BTM NTX as the outcome measures. Data on severe vertebral fractures, BTMs BALP, osteocalcin, NTX, and serum PINP were also extracted for summary and discussion. Original data collection forms were used to abstract the following information from single studies: sample size, dose, and changes from base line. Two reviewers screened articles independently, and disagreements were resolved through discussion. The Cochrane Collaboration's tool was used to assess risk of bias.

Evaluation of heterogeneity and statistics
------------------------------------------

RevMan software, version 5.3, was used for the calculation of heterogeneity parameter, quantitative meta-analyses, and generation of forest plots. The*I*^2^ value was calculated to determine the degree of heterogeneity. An*I*^2^ value from 50% to 75% represented moderate heterogeneity, and an*I*^2^ value above 75% was defined as high heterogeneity. In the presence of high heterogeneity, the random effect model was implemented. Risk ratios and their 95% confidence intervals (CIs) were calculated.

Results
=======

We identified 123 entries in MEDLINE, 176 entries in EMBASE, and 20 entries in Cochrane Central Register of Controlled Trials. As is shown in[Figure 1](#f1-dddt-10-509){ref-type="fig"}, a total of eleven studies were identified and analyzed. Among these studies, nine came from three independent trials using ELD as mono-therapy, involving 1,332 patients who were given placebo (n=53), alfacalcidol (n=546), or ELD (n=734). The first trial published in 2005 tested the effects of different doses of ELD on lumbar BMD, total hip BMD, and BTMs, including BALP, osteocalcin, NTX, BALP, and PINP.[@b24-dddt-10-509] The second trial published in 2010 compared between alfacalcidol and ELD the effects on BTMs BALP and NTX.[@b25-dddt-10-509] The third trial also compared the effects of alfacalcidol and ELD and the results were reported in multiple articles. In the report published in 2011, the effects of alfacalcidol and ELD on lumbar BMD and hip BMD were reported.[@b26-dddt-10-509] In the report published in 2012, their effects on NTX, BALP, and PINP were revealed.[@b27-dddt-10-509] The main features and their quantitative data synthesis are summarized in[Table 1](#t1-dddt-10-509){ref-type="table"}. Not all studies were included in[Table 1](#t1-dddt-10-509){ref-type="table"}, since some of them basically analyzed the same data from different angles.

The risk of bias assessment for these trials is presented in[Table 2](#t2-dddt-10-509){ref-type="table"}. Trials 1, 2, and 3 were found to be at moderate, high, and low risk of bias, respectively. The common problem for all the three trails was inadequate description of the randomization method and the overall risk of bias for all the trials was rated as moderate. The other two trials used ELD as a component in combination therapies. Results from these trials were excluded from our meta-analysis.

Among all parameters reported, only lumbar BMD, hip BMD, and NTX were examined in at least two independent trials. In the second trial, ELD increased the lumber and hip BMD by 3.1±0.7 and 0.9±0.5, respectively.[@b24-dddt-10-509] In the third trial, alfacalcidol increased the lumbar BMD by 0.2±0.4 but decreased hip BMD by 2.4±0.3, and ELD increased the lumber and hip BMD by 3.5±0.2 and 0.4±0.2, respectively.[@b26-dddt-10-509] Our meta-analyses found that at dose not less than 0.75 μg/day, ELD was able to significantly increase lumbar BMD with test for overall effect*Z*=6.35 (*P*\<0.00001) (HT*P*\<0.00001,*τ*^2^ =0.40,*χ*^2^ =58.5,*df*=1,*I*^2^=98%) ([Figure 2](#f2-dddt-10-509){ref-type="fig"}). Edecalcitol did not seem to increase total hip BMD though, with test for overall effect*Z*=1.00 (*P*=0.32) (Heterogeneity \[HT\]*P*\<0.00001,*τ*^2^ =3.92,*χ*^2^ =831.55,*df*=1,*I*^2^=100%) ([Figure 3](#f3-dddt-10-509){ref-type="fig"}).

All the three trials examined the effects of ELD on BTM NTX. In the first trial involving 219 osteoporotic patients, 1 μg/day of edecalcitol decreased urinary NTX from the baseline with a median percentage of 19% (*P*\<0.01).[@b24-dddt-10-509] In the second trial involving 59 Japanese postmenopausal women, suppression of urinary NTX was much stronger in both 0.5 and 1 μg ELD-treated groups than in 1 μg alfacalcidol-treated subjects, with urinary NTX decreasing by 6%, 30%, and 35% from the baseline, respectively.[@b25-dddt-10-509] In the third trial involving 1,054 patients, ELD-treated group (0.75 μg/day) was found to have lower urinary NTX than alfacalcidol-treated group (1 μg/day) (41±25 nmol vs 58±28 nmol,*P*\<0.05).[@b27-dddt-10-509] Since the effects of NTX were reported as medians of changes from the baseline in the first trial, the second and third trials reported only the means of NTX. Therefore, we carried out the meta-analysis for NTX using data only from the second and third trials, and the result, with test for overall effect*Z*=3.82 (*P*=0.0001) (HT*P*\<0.0001,*τ*^2^ =68.16,*χ*^2^ =18.76,*df*=1,*I*^2^=95%), suggested that ELD suppressed NTX to a greater degree when compared to alfacalcidol ([Figure 4](#f4-dddt-10-509){ref-type="fig"}).

In addition to NTX, some other BTMs were also investigated in these studies. In the first trial, ELD was found to suppress BALP with median percentages of 24% (*P*\<0.01), 19% (*P*\<0.01), and 23% (*P*\<0.01) and osteocalcin with median percentages of 30% (*P*\<0.01), 19% (*P*\<0.01), and 22% (*P*\<0.01). In the third trial, 0.75 μg/day of edecalcitol was found to do better than 1 μg/day of alfacalcidol in lowering serum BALP (26±9 vs 32±11 U/L,*P*\<0.05) and PINP (42±15 vs 59±23 ng/mL,*P*\<0.05).[@b27-dddt-10-509]

The third trial also compared the efficacy of 0.75 μg/day of edecalcitol and 1 μg/day of alfacalcidol in preventing osteoporotic fractures.[@b28-dddt-10-509] Their post hoc analyses found that ELD treatment reduced the incidence of osteoporotic fractures defined by the WHO Technical Report more than alfacalcidol treatment (18.6% vs 25.2%; hazard ratio \[HR\], 0.70; 95% CI, 0.54--0.93). ELD also decreased the incidence of major osteoporotic fractures defined in the WHO Fracture Risk Assessment Tool (FRAX) more than alfacalcidol (11.1% vs 16.3%; HR, 0.66; 95 % CI, 0.46--0.94).

The third trial further evaluated the effects of ELD on the spinal location of incident vertebral fractures, the severity of the fractures, and the changes in health-related quality of life (HRQOL) in comparison to those of alfacalcidol.[@b29-dddt-10-509] The incidence of vertebral fractures was evaluated based on the location on the spine (upper T4--T10; lower T11--L4). The severity of vertebral fractures was determined by using a semi-quantitative method, and the change in HRQOL was analyzed by using the Medical Outcomes Study Short-Form 36-Item questionnaire. The data showed that the incidence of vertebral fracture at the lower spine was less in the ELD group than in the alfacalcidol group (*P*=0.029), and the incidence of severe vertebral fracture (grade 3) was less in the ELD group than the alfacalcidol group (3.8% vs 6.7%,*P*=0.036). The data also revealed that both ELD and alfacalcidol improved HRQOL in osteoporotic patients. Although no significant differences in each HRQOL scores were observed between ELD and alfacalcidol during the observational period, overall improvement from baseline of HRQOL scores was clearly observed in the ELD group. In summary, compared to alfacalcidol, ELD could further reduce the incidences of lower spinal vertebral fractures and severe vertebral fractures. Furthermore, daily treatment with ELD was effective in improving HRQOL.

Conclusion and discussion
=========================

Vitamin D has long been regarded as a fundamental part of the prevention and treatment of osteoporosis. However, findings from observational studies showed inconsistent associations between BMD and vitamin D status.[@b30-dddt-10-509],[@b31-dddt-10-509] In fact, result from a recent meta-analysis of trials of vitamin D alone failed to show an association between supplementation and BMD.[@b32-dddt-10-509] In addition, results from meta-analyses of trials of vitamin D alone failed to show an association between supplementation and fracture prevention.[@b33-dddt-10-509],[@b34-dddt-10-509] Nevertheless, the active form of vitamin D, calcitriol, and its prodrug, alfacalcidol, have shown activities to increase BMD and reduce the risk of vertebral and nonvertebral fractures, and have been approved for the treatment of osteoporosis in Japan. Our current meta-analysis revealed that ELD was superior to alfacalcidol in suppressing NTX level. In fact, as was found in a recent clinical trial, alfacalcidol increased the lumbar BMD but decreased hip BMD, whereas ELD increased both the lumber and hip BMDs.[@b26-dddt-10-509] Our review of data from multiple clinical trials also showed that ELD performed better than alfacacidol in reducing incidence of severe vertebral fractures and suppressing BTMs, including serum BALP and PINP. Put together, current data have provided strong support to the notion that active vitamin D analogs could be tailored in ways to improve their beneficial effects while limiting the unwanted activities for treatment of diseases such as osteoporosis.

Other widely used drugs for osteoporosis include bisphosphonates, calcitonin, estrogen hormone, estrogen agonist/antagonist, PTH, and RANK ligand (RANKL)/RANKL inhibitor. Given the fact that the active analogs of vitamin D exert their pharmacological activities by mechanisms different from those of other current drugs, combination therapy with active vitamin D and other categories can be expected to offer more choices in osteoporosis treatment in the future. In fact, two such clinical trials have been conducted recently. In one trial, the effects of bisphosphonate alone on biochemical markers and muscle power in comparison with those of bisphosphonate combined with ELD were studied in postmenopausal women with osteoporosis. During the 6-month treatment period, while both treatments significantly reduced BTMs serum BALP and urinary NTX to a similar degree, combination therapy improved five-repetition chair-rising time to a significantly greater degree than monotherapy with bisphosphonate.[@b35-dddt-10-509] In another trial, efficacy of combination of alendronate and ELD was compared to that of combination of alendronate plus vitamin D and calcium in patients with primary osteoporosis. The results showed that alendronate combined with ELD was more effective in reducing the BTMs, including serum type I collagen C-telopeptide (sCTX), urine NTX, tartrate-resistant acid phosphatase 5b (TRACP-5b), BALP, and PINP and increasing the femoral neck BMD compared to alendronate treatment with vitamin D3 and calcium.[@b36-dddt-10-509] Therefore, ELD has shown promising potential in treatment of osteoporosis when combined with other existing antiosteoporotic drugs, and further exploration of ELD-based combination therapy is warranted.

Due to multiple reasons, our meta-analysis results should be interpreted and translated into clinical practice with caution. First of all, limited number of trials have been completed so far; second, risk of bias may be high in some of these trials; third, all trials have been conducted on Japanese patients, and the applicability of these data to other ethnic groups needs to be investigated; finally, data for some parameters were reported in different format in different trials (eg, interquartile in one study, but means in another study), making them less accurate and less comparable. However, over all clinical data that have been generated so far strongly support ELD as an effective treatment option for osteoporosis. Further clinical studies will surely reveal the full potential of ELD either as monotherapy or combination therapy for osteoporosis.
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![Flow diagram for study selection.\
**Abbreviation:** ELD, eldecalcitol.](dddt-10-509Fig1){#f1-dddt-10-509}

![Eldecalcitol increases lumbar BMD, as compared with placebo.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; BMD, bone mineral density;*df*, degree of freedom; MD, mean difference; SE, standard error.](dddt-10-509Fig2){#f2-dddt-10-509}

![Eldecalcitol has no effect on hip BMD, as compared to placebo.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; BMD, bone mineral density;*df*, degree of freedom; MD, mean difference; SE, standard error.](dddt-10-509Fig3){#f3-dddt-10-509}

![Eldecalcitol suppressed NTX to a greater degree in comparison with alfacalcidol.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; NTX, type I collagen amino-terminal telopeptide;*df*, degree of freedom; MD, mean difference; SE, standard error.](dddt-10-509Fig4){#f4-dddt-10-509}

###### 

Basic characteristics and results of clinical trials

  Author name                         Design                              Sample (n)             Interventions       Follow-up period   Lumber BMD (mean change, SEM, %)   Hip BMD (mean change, SEM, %)   Incidence of severe vertebral fractures\\ (mean)            Outcome                                                                                                                                                                         
  ----------------------------------- ----------------------------------- ---------------------- ------------------- ------------------ ---------------------------------- ------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------
  Matsumoto et al[@b24-dddt-10-509]   Double-blinded, RCT                 53                     Placebo             12 months          −0.7±0.5                           −0.9±0.5                                                                                    5 (26, −14)[a](#tfn1-dddt-10-509){ref-type="table-fn"}      12 (27, −11)[a](#tfn1-dddt-10-509){ref-type="table-fn"}    6 (33, −32)[a](#tfn1-dddt-10-509){ref-type="table-fn"}   
                                      55                                  Eldecalcitol 0.5 µg                        2.2±0.6            −0.8±0.6                                                           −24 (4, −38)[a](#tfn1-dddt-10-509){ref-type="table-fn"}     −30 (−10, −35)[a](#tfn1-dddt-10-509){ref-type="table-fn"}   −6 (15, −33)[a](#tfn1-dddt-10-509){ref-type="table-fn"}                                                             
                                      55                                  Eldecalcitol 0.75 µg                       2.6±0.5            0.6±0.4                                                            −19 (2, −40)[a](#tfn1-dddt-10-509){ref-type="table-fn"}     −19 (2, −37)[a](#tfn1-dddt-10-509){ref-type="table-fn"}     −17 (28, −40)[a](#tfn1-dddt-10-509){ref-type="table-fn"}                                                            
                                      56                                  Eldecalcitol 1 µg                          3.1±0.7            0.9±0.5                                                            −23 (−14, −38)[a](#tfn1-dddt-10-509){ref-type="table-fn"}   −22 (−6, −39)[a](#tfn1-dddt-10-509){ref-type="table-fn"}    −19 (0, −34)[a](#tfn1-dddt-10-509){ref-type="table-fn"}                                                             
  Matsumoto et al[@b25-dddt-10-509]   Randomized, active comparator       20                     Alfacalcidol 1 µg   12 weeks                                                                                                                                          −22±3[b](#tfn2-dddt-10-509){ref-type="table-fn"}                                                                       −6±8[b](#tfn2-dddt-10-509){ref-type="table-fn"}          
                                      19                                  Eldecalcitol 0.5 µg                                                                                                              −22±2[b](#tfn2-dddt-10-509){ref-type="table-fn"}                                                                        −30±6[b](#tfn2-dddt-10-509){ref-type="table-fn"}                                                                    
                                      20                                  Eldecalcitol 1 µg                                                                                                                −29±1[b](#tfn2-dddt-10-509){ref-type="table-fn"}                                                                        −35±6[b](#tfn2-dddt-10-509){ref-type="table-fn"}                                                                    
  Matsumoto et al[@b26-dddt-10-509]   Randomized, DB, active comparator   526                    Alfacalcidol 1 µg   36 months          0.2±0.4                            −2.4±0.3                                                                                                                                                                                                                                                                    
                                      528                                 Eldecalcitol 0.75 µg                       3.5±0.2            0.4±0.2                                                                                                                                                                                                                                                                                                        
  Shiraki et al[@b27-dddt-10-509]     Randomized, DB, active comparator   526                    Alfacalcidol 1 µg   36 months                                                                                                                                         32±11[c](#tfn3-dddt-10-509){ref-type="table-fn"}                                                                       58±28[c](#tfn3-dddt-10-509){ref-type="table-fn"}         59±23[c](#tfn3-dddt-10-509){ref-type="table-fn"}
                                      528                                 Eldecalcitol 0.75 µg                                                                                                             26±9[c](#tfn3-dddt-10-509){ref-type="table-fn"}                                                                         41±25[c](#tfn3-dddt-10-509){ref-type="table-fn"}           42±15[c](#tfn3-dddt-10-509){ref-type="table-fn"}         
  Hagino et al[@b29-dddt-10-509]      Randomized, DB, active comparator   526                    Alfacalcidol 1 µg   36 months                                                                             6.70%                                                                                                                                                                                                                                       
                                      528                                 Eldecalcitol 0.75 µg                                                                             3.80%                                                                                                                                                                                                                                                                       

**Notes:**

Denotes median, interquartile range (change from baseline);

denotes means ± SEM (change from baseline);

denotes means ± SD (absolute value).

**Abbreviations:** BMD, bone mineral density; SEM, standard error of the mean; BALP, bone alkaline phosphatase; NTX, type I collagen amino-terminal telopeptide; BCE, bone collagen; Cr, creatinine; PINP, amino-terminal propeptide of procollagen I; RCT, randomized control trial; DB, Double-blinded; SD, standard deviation.

###### 

Assessment of risk of bias by The Cochrane Collaboration's tool

  Type of risk of bias                              Trial 1   Trial 2   Trial 3
  ------------------------------------------------- --------- --------- ---------
  Random sequence generation (selection bias)       Unclear   Unclear   Unclear
  Allocation concealment (selection bias)           Unclear   No        Yes
  Blinding of outcome assessment (detection bias)   Yes       Unclear   Yes
  Incomplete outcome data (attrition bias)          Yes       Unclear   Yes
  Selective reporting (reporting bias)              Yes       Unclear   Yes
